.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BD20_MetforminAndEmpagliflozi.MetforminAndEmpagliflozi .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BD20_MetforminAndEmpagliflozi.MetforminAndEmpagliflozi| name: | MetforminAndEmpagliflozin |
| ATC code: | A10BD20 | route: | oral |
| n-compartments | 1 |
A fixed-dose combination of metformin (a biguanide that decreases hepatic glucose production and improves insulin sensitivity) and empagliflozin (a sodium-glucose co-transporter 2, SGLT2 inhibitor that reduces glucose reabsorption in the kidney). Used for the treatment of type 2 diabetes mellitus to improve glycemic control in adults; both substances are approved and widely used in combination therapy.
Estimated pharmacokinetic parameters for healthy adult subjects after oral administration, as no published population PK studies were found for the fixed-dose combination product. Parameters are approximate and based on known PK of separate metformin and empagliflozin oral administration.
Scheen, AJ (2015). Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs 75(1) 33–59. DOI:10.1007/s40265-014-0337-y PUBMED:https://pubmed.ncbi.nlm.nih.gov/25488697